A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
- To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in
combination with other cancer therapies in study participants with hematologic
malignancies.
- To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007
or ERAS-601 administered in combination with other cancer therapies.
- To evaluate the preliminary efficacy of ERAS-007 or ERAS-601 in combination with other
cancer therapies in study participants with hematologic malignancies.
- To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when
administered in combination.